Platform Development

About Aurora Therapeutics

Aurora Therapeutics was launched to solve the fundamental scalability problem in rare disease treatment, where over 350 million people worldwide lack therapies targeting their specific genetic mutations. The company is developing a platform that leverages CRISPR gene editing tools, which can be rapidly tailored to specific mutations with increasing precision, to create personalized treatments at scale. Led by CEO Edward M. Kaye and backed by investors like Menlo Ventures, Aurora is assembling a team of leaders in gene editing, rare-disease medicine, and therapeutic development to realize the potential of personalized gene editing for millions of patients.

About PurCell Bio

PurCell Bio is a private, pre-clinical stage biotech firm pioneering cell therapy platforms aimed at tissue regeneration. Operating in the high-growth sectors of cell therapy and regenerative medicine, the company is positioned to tackle significant conditions like musculoskeletal and cardiac injuries. As a pre-revenue entity, its success hinges on advancing its platform through preclinical validation and securing strategic partnerships or funding to reach clinical trials. The company faces typical early-stage biotech risks, including scientific, regulatory, and competitive challenges.

About Angstrom Bio

Angstrom Bio is an early-stage diagnostics company founded in 2020, combining machine intelligence with proprietary nucleotide chemistry to enhance amplicon sequencing. The company aims to develop highly sensitive, specific, and accessible diagnostic tools for a broad range of diseases. Operating from Austin, Texas, it is positioned at the intersection of computational biology and wet-lab innovation, targeting significant improvements in diagnostic accuracy and scalability. As a private entity, it is likely in a pre-revenue, R&D-focused stage, building its foundational technology platform.

About GRIP Molecular Technologies

GRIP Molecular Technologies is developing a next-generation diagnostic platform that combines the precision of molecular testing with the simplicity and speed of lateral flow assays. Its core innovation is a CRISPR protease engine that detects pathogen RNA and amplifies signal in minutes at room temperature, eliminating the need for complex nucleic acid pre-amplification steps. The platform is designed to be pathogen-agnostic and adaptable to various sample types and readout formats, targeting the significant unmet need for fast, accurate, and affordable diagnostics in point-of-need settings. With a focus on a multi-billion dollar market for STI, UTI, and URI testing, GRIP aims to close the gap between centralized lab testing and decentralized clinical demand.

About Bio-Sourcing

Bio-Sourcing is a private, pre-revenue biotech company leveraging a breakthrough platform that combines CRISPR-Cas9 gene editing, nuclear transfer, and reproductive technologies to produce biopharmaceuticals in goat milk. This approach promises to drastically reduce capital costs and production expenses while increasing scalability, targeting the global unmet need for affordable monoclonal antibodies. The company, led by an experienced team of scientists, positions its technology as a solution for both Western and emerging economies to improve access to biologics, particularly during pandemics.

About Cambridge Medical Technologies

Cambridge Medical Technologies is a private, pre-revenue developer of a novel diagnostic platform for continuous biomarker monitoring. Its core technology involves minimally invasive, nano-scale devices that sample interstitial fluid and use electrochemistry to detect blood analytes, targeting the need for real-time, trended patient data in chronic disease management. With operations in the UK, US, and Japan, the company is led by a seasoned executive team with deep experience in medtech, finance, and engineering, positioning it to address a significant gap in the digital health diagnostics market.

About bYoRNA

bYoRNA is an early-stage biotech developing a proprietary, cost-effective mRNA bioproduction platform using engineered eukaryotic cells to accumulate and isolate therapeutic mRNA. The company aims to address the scalability and cost challenges of traditional mRNA manufacturing to enable broader therapeutic applications in oncology, infectious diseases, and rare genetic disorders. Founded by seasoned executives with backgrounds in high-tech entrepreneurship and biopharmaceutical development, bYoRNA is positioning itself as a potential enabler for the next generation of RNA therapeutics. Its platform is currently in the pre-clinical/process development stage.

About SunVax mRNA Therapeutics

SunVax mRNA Therapeutics is an early-stage biotech leveraging a combined LNP and self-amplifying mRNA platform to create targeted therapies. The company emphasizes rapid formulation capabilities (under 40 minutes) and ease of use, targeting a broad range of cell types and therapeutic areas. Operating as a private, pre-revenue entity, SunVax is positioned in the competitive but high-growth field of advanced drug delivery and mRNA therapeutics, with its success hinging on platform validation and clinical translation.

About Transimmune

Transimmune is a private, pre-clinical stage biotech leveraging a novel dendritic cell platform derived from the mechanistic understanding of Extracorporeal Photopheresis (ECP). Its core technology uses platelet-activated monocytes to generate dendritic cells in hours, promising enhanced potency and point-of-care manufacturing. The company is advancing programs in cancer and infectious disease vaccines, backed by grants and collaborations with academic institutions and industry partners like Mallinckrodt.

Therapeutic Areas

Other Rare Genetic Diseases Drugs